MicroRNA encapsulated nanocells - EnGeneIC

Drug Profile

MicroRNA encapsulated nanocells - EnGeneIC

Alternative Names: EGFREDVmiR-16; MicroRNA packaged EDVTM nanocells - EnGeneIC; TargomiR; TargomiRs - EnGeneIC

Latest Information Update: 08 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator EnGeneIC
  • Developer Asbestos Diseases Research Institute; EnGeneIC; University of Sydney
  • Class Antineoplastics; Cell therapies; MicroRNAs
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Mesothelioma

Most Recent Events

  • 05 Sep 2017 Updated efficacy and adverse events data from the phase I/IIa MesomiR 1 trial in Mesothelioma released by EnGeneIC
  • 27 Mar 2017 Phase-I/II development for Mesothelioma (Late-stage disease, Second-line therapy or greater) is ongoing in Australia (IV)
  • 01 Jan 2017 EnGeneIC completes a phase I/II trial for Mesothelioma (Late-stage disease, Second-line therapy or greater) in Australia (IV) (NCT02369198)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top